Enhancing radiosensitivity: Targeting the DNA repair pathways

Cancer Biology and Therapy

Volumn 8, Issue 8, 2009, Pages 665-670

  Jorgensen, Timothy J ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; DNA repair; Hypoxic; Poly(ADP ribose) polymerase; Radiation biology; Radiotherapy; Synthetic lethal

Indexed keywords

AG 014699; ANTINEOPLASTIC AGENT; AZD 2281; BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER RADIOTHERAPY; CELL CYCLE ARREST; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; HUMAN; HYPOXIA; IONIZING RADIATION; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW;

EID: 66149110742     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.8.8304     Document Type: Review

References (65)

1. Gerweck LE, Vijayappa S, Kurimasa A, Ogawa K, Chen DJ. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res 2006; 66:8352-8355 (Pubitemid 44449143)
2. Weichselbaum RR, Beckett MA, Hallahan DE, Kufe DW, Vokes EE. Molecular targets to overcome radioresistance. Semin Oncol 1992; 19:14-20.
3. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol 2007; 19:397-417. (Pubitemid 46995615)
4. Nunez MI, McMillan TJ, Valenzuela MT, Ruiz de Almodovar JM, Pedraza V. Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Radiother Oncol 1996; 39:155-165 (Pubitemid 26150455)
5. Chistiakov DA, Voronova NV, Chistiakov PA. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol 2008; 47:809-824
6. th Ed. New York: Lippincott Williams & Wilkins 2000.
7. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA doublestrand breaks by non-homologous end-joining. Biochem J 2009; 417:639-650
8. Hakem R. DNA-damage repair; the good, the bad and the ugly. EMBO J 2008; 27:589-605.
9. Trott KR. Experimental results and clinical implications of the four R's in fractionated radiotherapy. Radiat Environ Biophys 1982; 20:159-170 (Pubitemid 12079014)
10. Shibata D. When does MMR loss occur during HNPCC progression? Cancer Biomark 2006; 2:29-35.
11. Powell SN, Kachnic LA. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 2008; 8:448-460
12. Altieri F, Grillo C, Maceroni M, Chichiarelli S. DNA damage and repair: from molecular mechanisms to health implications. Antioxid Redox Signal 2008; 10:891-937.
13. Kelley MR, Fishel ML. DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem 2008; 8:417-425
14. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204.
15. Ooi SL, Pan X, Peyser BD, Ye P, Meluh PB, Yuan DS, et al. Global synthetic-lethality analysis and yeast functional profiling. Trends Genet 2006; 22:56-63. (Pubitemid 43011998)
16. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-698 (Pubitemid 41486362)
17. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638-642
18. Helleday T. Amplifying tumour-specific replication lesions by DNA repair inhibitors - a new era in targeted cancer therapy. Eur J Cancer 2008; 44:921-927
19. Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 1995; 14:149-161
20. Lane DP. Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harb Symp Quant Biol 2005; 70:489-497 (Pubitemid 44124906)
21. Okaichi K, Ide-Kanematsu M, Izumi N, Morita N, Okumura Y, Ihara M. Variations in sensitivity to ionizing radiation in relation to p53 mutation point. Anticancer Res 2008; 28:2687-2690
22. Ghoshal S, Dey P, Saikia UN, Sharma SC. Prognostic value of p53 overexpression in head and neck carcinomas: a pilot study. Anal Quant Cytol Histol 2002; 24:254-256 (Pubitemid 35191465)
23. Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Puig P. Prognostic value of p53 mutations in rectal carcinoma. Int J Cancer 2002; 100:131-135 (Pubitemid 34666184)
24. Petersen S, Thames HD, Nieder C, Petersen C, Baumann M. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis Colon Rectum 2001; 44:322-333 (Pubitemid 32226320)
25. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation and adjuvant treatment. J Clin Oncol 2005; 23:7518-7528 (Pubitemid 46291815)
26. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996; 42:858-868 (Pubitemid 126664238)
27. WAF1/CIP1-/- human cancer cells. Cancer Res 1996; 56:2250-2255
28. WAF1/CIP1 expression by p53-independent pathways. Oncogene 1996; 12:1557-1564
29. Tian H, Wittmack EK, Jorgensen TJ. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 2000; 60:679-684 (Pubitemid 30094567)
30. 1 arrest in human cancer cells. Cancer Res 1995; 55:5187-5190
31. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8:180-192
32. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008; 68:605-614
33. Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, et al. Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann N Y Acad Sci 2005; 1059:184-195 (Pubitemid 43211621)
34. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, et al. Hypoxia-induced downregulation of BRCA1 expression by E2Fs. Cancer Res 2005; 65:11597-11604 (Pubitemid 41821719)
35. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, et al. Hypoxia downregulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005; 76:168-176 (Pubitemid 41725444)
36. Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, et al. Downregulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004; 24:8504-8518 (Pubitemid 39245072)
37. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278:1064-1068 (Pubitemid 27517876)
38. Chan DA, Giaccia AJ. Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics. Cell Cycle 2008; 7:2987-2990
39. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008; 18:80-86
40. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26:3785-3790
41. De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, et al. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci 2006; 2:179-185 (Pubitemid 44031562)
42. De Soto JA, Deng CX. PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? Int J Med Sci 2006; 3:117-123
43. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005; 4:934-936 (Pubitemid 41598586)
44. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-921 (Pubitemid 40559006)
45. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Res 2006; 66:8109-8115 (Pubitemid 44299177)
46. Noel G, Giocanti N, Fernet M, Megnin-Chanet F, Favaudon V. Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery. BMC Cell Biol 2003; 4:7. (Pubitemid 38597763)
47. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004; 279:55117-55126 (Pubitemid 40066505)
48. Brown ET, Holt JT. Rad51 overexpression rescues radiation resistance in BRCA2-defective cancer cells. Mol Carcinog 2009; 48:105-109
49. Shen SX, Weaver Z, Xu X, Li C, Weinstein M, Chen L, et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 1998; 17:3115-3124 (Pubitemid 29020807)
50. 2-M delay. Clin Cancer Res 1997; 3:1149-1156
51. Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci 2008; 99:1734-1740
52. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812
53. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-1806
54. Parmigiani G, Boca S, Lin J, Kinzler KW, Velculescu V, Vogelstein B. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 2009; 93:17-21.
55. Ashworth A. Drug resistance caused by reversion mutation. Cancer Res 2008; 68:10021-10023
56. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451:1116-1120
57. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451:1111-1115
58. Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw 2005; 3:291-300. (Pubitemid 44265435)
59. Ogawa K, Murayama S, Mori M. Predicting the tumor response to radiotherapy using microarray analysis. Oncol Rep 2007; 18:1243-1248
60. Travis LB. Therapy-associated solid tumors. Acta Oncol 2002; 41:323-333
61. Howard RA, Gilbert ES, Chen BE, Hall P, Storm H, Pukkala E, et al. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat 2007; 105:359-368 (Pubitemid 47596449)
62. Wyman C, Kanaar R. DNA double-strand break repair: all's well that ends well. Annu Rev Genet 2006; 40:363-383
63. Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008; 270:1-9.
64. Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009; 101:205-209
65. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, et al. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res 2007; 9:26. (Pubitemid 350215161)